ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
Provided By PR Newswire
Last update: May 14, 2025
LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability
Read more at prnewswire.com
